₹-0.25
(Market cap
₹2,164 Cr
Recently Viewed
Clear AllMarket cap
₹2,164 Cr
Revenue (TTM)
₹-- Cr
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹0 Cr
ROE
0 %
ROCE
-2.9 %
Industry P/E
60.11
EV/EBITDA
-8013.3
Debt to Equity
-1.8
Book Value
₹-2.1
EPS
₹-0.1
Face value
10
Shares outstanding
54,567,765
CFO
₹609.41 Cr
EBITDA
₹973.84 Cr
Net Profit
₹663.74 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Claris Lifesciences
| 11.3 | 1.7 | 13.0 | 24.4 | 13.7 | 16.1 | -- |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
BSE Healthcare#
| -2.4 | -2.6 | -3.9 | 5.9 | 24.1 | 13.8 | 10.8 |
|
Company
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|
|
Claris Lifesciences
| 11.3 | 48.4 | 19.0 | -9.1 |
|
BSE Sensex
| 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| 0.5 | -12.9 | 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Claris Lifesciences
|
396.6 | 2,163.9 | 13.9 | -0.3 | -434.7 | 0 | -- | 0.7 |
| 2,322.1 | 18,980.2 | 1,215.1 | 284.8 | 28.7 | 21.1 | 66.1 | 12.5 | |
| 720.2 | 14,250.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 22.7 | 2.6 | |
| 635.5 | 15,702.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.8 | 3.5 | |
| 879.0 | 13,992.1 | 7,918.4 | 429.9 | 10.7 | 7.2 | 32.3 | 2.1 | |
| 1,123.7 | 19,977.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.8 | 2.3 | |
| 1,375.7 | 15,817.7 | 1,419.3 | 20.1 | 8.4 | 0.5 | 786.9 | 2.7 | |
| 143.0 | 18,948.4 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 393.1 | 15,952.4 | 3,720.2 | 352.1 | 13.7 | 8.2 | 45.3 | 3.4 | |
| 1,369.7 | 22,505.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1023 | 4.9 |
1 min read•By Research Desk
Wholesale of pharmaceutical and medical goods
Incorporated
1994
Chairman
Surrinder Lal Kapur
Managing Director
Arjun Handa
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Claris Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsAnnouncement under Regulation 30 (LODR)-Updates
12-Mar-2018Announcement under Regulation 30 (LODR)-Updates
12-Mar-2018Announcement under Regulation 30 (LODR)-Updates
22-Feb-2018
The share price of Claris Lifesciences Ltd is ₹396.55 (BSE) as of 14-Mar-2018 IST. Claris Lifesciences Ltd has given a return of 13.7% in the last 3 years.
Since, TTM earnings of Claris Lifesciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Claris Lifesciences Ltd is 0.74 times as on 14-Mar-2018, a 81 discount to its peers’ median range of 3.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
0.00
|
0.00
|
|
2020
|
0.00
|
0.00
|
|
2019
|
0.00
|
0.00
|
|
2018
|
127.31
|
3,071.96
|
|
2017
|
15.91
|
1.71
|
The 52-week high and low of Claris Lifesciences Ltd are Rs -- and Rs -- as of 09-Apr-2026.
Claris Lifesciences Ltd has a market capitalisation of ₹ 2,164 Cr as on 14-Mar-2018. As per SEBI classification, it is a company.
Before investing in Claris Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.